Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:19 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 1,898 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Effect of Drug Clear all

Conditions: Cardiotoxicity, Heart Failure, Breast Cancer, Anthracycline Induced Cardiomyopathy, Biomarkers, Echocardiography
Interventions: Not listed
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years to 85 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Lennox-Gastaut Syndrome
Interventions: Rufinamide, Any other approved Antiepileptic Drug; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 1 Year to 3 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 22
States / cities: San Diego, California • Aurora, Colorado • Washington D.C., District of Columbia + 19 more

Conditions: Healthy Volunteers
Interventions: IP, Matching Placebo; Drug
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: LY3871801, Methotrexate, Warfarin, Dextromethorphan, Midazolam, Repaglinide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Macular Edema
Interventions: AIV007; Drug
Lead sponsor: AiViva BioPharma, Inc.; Industry
Eligibility: 21 Years to 90 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Beverly Hills, California • Santa Ana, California • Eugene, Oregon + 3 more

Conditions: Healthy
Interventions: Palbociclib, Rifampin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Carcinoma
Interventions: Nurse, Non-nurse coach; Behavioral
Lead sponsor: Michigan State University; Other
Eligibility: 21 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: East Lansing, Michigan

Conditions: Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2, Pneumonia, Pneumonia, Viral, Lung Diseases, Respiratory Tract Disease, Respiratory Tract Infections, Coronaviridae Infections, Nidovirales Infections, RNA Virus Infections, Virus Disease, Immunologic Disease, ARDS, Immunologic Factors, Physiological Effects of Drugs, Antiviral Agents, Anti-infective Agents, Analgesics, Antimetabolites, Antineoplastic
Interventions: CYNK-001; Biological
Lead sponsor: Celularity Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 4
States / cities: Irvine, California • Morristown, New Jersey • Summit, New Jersey + 1 more

Conditions: Healthy Volunteers
Interventions: PF-04171327 25 mg, Midazolam 2 mg; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Schizophrenia
Interventions: SEP363856 150 mg, Placebo, moxifloxacin 400 mg; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 7
States / cities: Little Rock, Arkansas • Long Beach, California • Pico Rivera, California + 4 more

Conditions: Brain Tumor, Central Nervous System Tumor, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Liver Cancer, Neuroblastoma, Ototoxicity, Ovarian Cancer, Sarcoma
Interventions: sodium thiosulfate, examination; Drug · Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 18 Years
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2021
U.S. locations: 68
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 61 more

Conditions: Obesity, Overweight and/or Obesity, Overweight, Drug Interaction
Interventions: PF-08653944, Acetaminophen; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Patient Handoff
Interventions: Handoff Workshop; Other
Lead sponsor: George Washington University; Other
Eligibility: Not listed
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Healthy
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Glendale, California

Conditions: Smoking
Interventions: Abstain from smoking for 24 hours; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Vitamin B1 Deficiency, Thiamine Deficiency
Interventions: Trimethoprim, Metformin, Vitamin B1; Drug · Dietary Supplement
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Non Small Cell Lung Cancer
Interventions: Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Rosuvastatin, Pharmacokinetic sampling - rosuvastatin, Pharmacokinetic sampling - AZ5140 and AZ7550; Procedure · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Behavior, Risk
Interventions: 3x3 between-subjects experimental exposure; Behavioral
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Driving Behavior, Driving Under the Influence
Interventions: Placebo (Lactose) Capsule, 0.75 mg Alprazolam Capsule, Cannabis (6.18% THC / <0.025% CBD), Cannabis (0%/ THC / 0% CBD); Drug
Lead sponsor: Timothy L. Brown; Other
Eligibility: 19 Years to 45 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Parkinson's Disease, Drug-induced Parkinsonism
Interventions: Exercise; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years to 89 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Breast Neoplasms, Lymphoma, Sarcoma
Interventions: Echocardiogram; Procedure
Lead sponsor: Daniel Rushing; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: RSV Infection
Interventions: EDP-938, Tacrolimus, Dabigatran, Rosuvastatin, Midazolam; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Hypothalamic Obesity
Interventions: Exenatide, placebo; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 10 Years to 25 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Nashville, Tennessee • Seattle, Washington

Conditions: Healthy, Obese, Overweight
Interventions: Orforglipron, Simvastatin, Digoxin, Rosuvastatin, Acetaminophen, Midazolam, Sodium Bicarbonate; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Search by objective public record fields.

Novel Biomarkers and Echocardiography for Subclinical Cardiac Toxicity in Breast Cancer Patients Receiving Anthracyclines

Study of Rufinamide in Pediatric Subjects 1 to Less Than 4 Years of Age With Lennox-Gastaut Syndrome Inadequately Controlled With Other Anti-epileptic Drugs

A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects

A Drug Interaction Study of LY3871801 in Healthy Participants

Effect of AIV007 by Periocular Administration in Subjects With Macular Edema Secondary to nAMD and DME

A Study To Investigate The Drug-Drug Interaction Potential Of Rifampin OnThe Investigational Agent Palbociclib (PD-0332991)

Pain and Fatigue Study

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

A Midazolam Drug Interaction Study With PF-04171327

A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity

Effect of Hand-off Skills Training for Students During the Medicine Clerkship

Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male Adults

The Effects of Smoking Withdrawal On Resting State Functional Connectivity

The Effect of SLC19A3 Inhibition on the Pharmacokinetics of Thiamine

Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer

Human Laboratory Study of the Effects of Nicotine Product Claims on Appeal, Perceptions, and Use Behavior

Validation of the Drug Impaired Driving Scenario (DIDS) on the CRCDS-miniSim

Effect of Exercise in Parkinsonism

Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Chemotherapy Containing Doxorubicin

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity

A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants